Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDX [NASD]
Ardelyx, Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own1.10% Shs Outstand100.04M Perf Week3.64%
Market Cap122.70M Forward P/E- EPS next Y-1.22 Insider Trans-1.94% Shs Float75.14M Perf Month-12.31%
Income-125.30M PEG- EPS next Q-0.35 Inst Own84.60% Short Float8.81% Perf Quarter-33.33%
Sales12.40M P/S9.90 EPS this Y28.50% Inst Trans0.24% Short Ratio0.95 Perf Half Y-86.48%
Book/sh1.18 P/B0.97 EPS next Y17.50% ROA-61.50% Target Price4.20 Perf Year-78.41%
Cash/sh1.60 P/C0.71 EPS next 5Y30.00% ROE-99.10% 52W Range1.01 - 9.23 Perf YTD-82.38%
Dividend- P/FCF- EPS past 5Y4.00% ROI-51.30% 52W High-87.65% Beta1.76
Dividend %- Quick Ratio3.20 Sales past 5Y-20.60% Gross Margin91.90% 52W Low12.87% ATR0.08
Employees129 Current Ratio3.20 Sales Q/Q-27.80% Oper. Margin- RSI (14)41.68 Volatility6.61% 6.36%
OptionableYes Debt/Eq0.44 EPS Q/Q-61.20% Profit Margin- Rel Volume0.36 Prev Close1.15
ShortableYes LT Debt/Eq0.13 Earnings- Payout- Avg Volume6.94M Price1.14
Recom2.00 SMA20-5.51% SMA50-12.67% SMA200-78.01% Volume2,517,671 Change-0.87%
Oct-14-21Downgrade Ladenburg Thalmann Buy → Neutral
Jul-21-21Downgrade Jefferies Buy → Hold $11 → $2
Jul-20-21Downgrade Wedbush Outperform → Neutral $3
Jul-20-21Downgrade Piper Sandler Overweight → Neutral $14 → $4
Mar-23-21Initiated Wedbush Outperform $14
Jan-06-21Initiated Cantor Fitzgerald Overweight $14
Oct-20-20Resumed Citigroup Buy $13
Feb-18-20Resumed Jefferies Buy $11
Feb-12-20Initiated Citigroup Buy $13
Feb-10-20Initiated Cowen Outperform
Apr-08-19Initiated Piper Jaffray Overweight $15
Aug-24-18Initiated Jefferies Buy $7
Mar-19-18Resumed Leerink Partners Outperform $13
Nov-29-17Reiterated Citigroup Buy $16 → $17
Nov-22-17Reiterated Ladenburg Thalmann Buy $19 → $16
Oct-17-17Resumed Leerink Partners Outperform
Mar-31-16Initiated Ladenburg Thalmann Buy
Mar-09-16Initiated Cantor Fitzgerald Buy $19
Mar-03-16Initiated Citigroup Buy
Oct-27-21 10:49AM  
Oct-13-21 05:00PM  
08:00AM  
Sep-30-21 06:27PM  
Sep-29-21 01:11PM  
Sep-28-21 12:22PM  
10:57AM  
09:20AM  
09:09AM  
07:50AM  
05:40AM  
Sep-27-21 09:15PM  
08:45PM  
12:10PM  
10:53AM  
10:00AM  
10:00AM  
08:30AM  
05:19AM  
Sep-26-21 03:15PM  
12:00PM  
Sep-24-21 05:00PM  
03:45PM  
12:20PM  
11:00AM  
11:00AM  
09:58AM  
09:45AM  
08:15AM  
Sep-23-21 08:51PM  
07:20PM  
11:35AM  
11:00AM  
09:15AM  
08:28AM  
05:40AM  
Sep-22-21 09:08PM  
06:35PM  
05:03PM  
04:17PM  
12:10PM  
08:00AM  
Sep-21-21 03:40PM  
02:22PM  
09:00AM  
08:20AM  
Sep-20-21 07:15PM  
06:40PM  
10:40AM  
10:07AM  
09:20AM  
08:20AM  
06:21AM  
Sep-19-21 10:21AM  
Sep-18-21 10:02AM  
Sep-17-21 07:15PM  
06:00PM  
05:39PM  
11:45AM  
11:00AM  
09:15AM  
08:45AM  
06:00AM  
Sep-16-21 03:25PM  
08:45AM  
Sep-15-21 09:14PM  
08:57PM  
08:15PM  
11:30AM  
10:25AM  
Sep-14-21 07:36PM  
06:09PM  
11:05AM  
10:43AM  
09:33AM  
Sep-13-21 06:10PM  
05:37PM  
02:13PM  
12:40PM  
11:35AM  
10:50AM  
10:39AM  
10:30AM  
10:00AM  
09:00AM  
05:40AM  
Sep-12-21 12:01PM  
10:30AM  
Sep-10-21 08:16PM  
07:16PM  
05:45PM  
04:35PM  
02:55PM  
01:25PM  
11:35AM  
11:00AM  
10:00AM  
09:27AM  
Sep-09-21 03:00PM  
02:15PM  
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenbaum David P.Chief Development OfficerAug 20Sale1.3217623226,574Aug 24 06:08 PM
Rosenbaum David P.Chief Development OfficerAug 20Sale1.32631833158,804Aug 24 06:08 PM
RAAB MICHAELPresident & CEOAug 20Sale1.322,5733,396329,730Aug 24 06:06 PM
Renz Justin AChief Financial OfficerAug 20Sale1.3263183340,047Aug 24 06:07 PM
Rodriguez SusanChief Commercial OfficerAug 20Sale1.3263083244,673Aug 24 06:07 PM
Jacobs Jeffrey WChief Scientific OfficerAug 20Sale1.32741978127,697Aug 24 06:06 PM
Blanks RobertSee RemarksAug 20Sale1.32631833106,323Aug 24 06:05 PM
GRAMMER ELIZABETH ASee RemarksAug 20Sale1.32526694102,386Aug 24 06:05 PM
RAAB MICHAELPresident & CEOAug 03Option Exercise0.54267,892144,662482,646Aug 05 05:01 PM
Jacobs Jeffrey WChief Scientific OfficerAug 03Option Exercise0.5410,0005,400134,051Aug 05 05:00 PM
Jacobs Jeffrey WChief Scientific OfficerJun 15Option Exercise0.547,5004,050131,551Jun 17 04:32 PM
Jacobs Jeffrey WChief Scientific OfficerJun 15Sale7.297,50054,658124,051Jun 17 04:32 PM
Rosenbaum David P.Chief Development OfficerMay 28Sale7.223,06222,09826,750Jun 02 07:23 PM
Rosenbaum David P.Chief Development OfficerMay 20Sale7.091571,11329,812May 21 04:49 PM
Rosenbaum David P.Chief Development OfficerMay 20Sale7.096124,338159,435May 21 04:49 PM
Rodriguez SusanChief Commercial OfficerMay 20Sale7.096114,33145,303May 21 04:49 PM
RAAB MICHAELPresident & CEOMay 20Sale7.092,53417,960214,754May 21 04:47 PM
Renz Justin AChief Financial OfficerMay 20Sale7.096124,33840,678May 21 04:48 PM
Blanks RobertSee RemarksMay 20Sale7.096124,338106,954May 21 04:46 PM
GRAMMER ELIZABETH ASee RemarksMay 20Sale7.095083,601102,912May 21 04:46 PM
Jacobs Jeffrey WChief Scientific OfficerMay 20Sale7.097215,110124,051May 21 04:47 PM
Rosenbaum David P.Chief Development OfficerApr 06Sale8.005,00040,000160,047Apr 08 06:20 PM
Blanks RobertSee RemarksFeb 22Sale6.885934,081112,729Feb 24 04:50 PM
Jacobs Jeffrey WChief Scientific OfficerFeb 22Sale6.887024,832124,772Feb 24 04:41 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale6.881931,32829,969Feb 24 04:38 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale6.886124,212165,047Feb 24 04:38 PM
Rodriguez SusanChief Commercial OfficerFeb 22Sale6.886114,20545,914Feb 24 04:40 PM
Renz Justin AChief Financial OfficerFeb 22Sale6.886084,18541,290Feb 24 04:37 PM
RAAB MICHAELPresident & CEOFeb 22Sale6.882,53417,440217,288Feb 24 04:39 PM
GRAMMER ELIZABETH ASee RemarksFeb 22Sale6.885043,469103,420Feb 24 04:36 PM
Jacobs Jeffrey WChief Scientific OfficerDec 21Sale6.883,94927,15392,862Dec 22 04:10 PM
GRAMMER ELIZABETH ASee RemarksDec 14Option Exercise2.3241,00095,120113,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 14Sale7.3041,000299,30072,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 11Option Exercise2.321,0002,32073,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 11Sale7.301,0007,30072,527Dec 15 04:22 PM
MOTT DAVID MDirectorDec 10Buy5.89170,0001,000,841417,284Dec 10 06:22 PM